News Conference News CRT 2025 AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years L.A. McKeown March 10, 2025
News Conference News CRT 2024 Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries L.A. McKeown March 14, 2024
News Conference News CRT 2024 Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis L.A. McKeown March 09, 2024
News Conference News BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years Caitlin E. Cox March 02, 2022
News Conference News CRT 2021 Polymer-Free Stent Noninferior to ZES at 3 Years: ReCre8 Yael L. Maxwell March 18, 2021
News Conference News CRT 2021 BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients Caitlin E. Cox March 16, 2021
News Conference News CRT 2020 Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback Michael O'Riordan February 28, 2020
News Conference News CRT 2020 BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis L.A. McKeown February 25, 2020
News Conference News CRT 2019 Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy L.A. McKeown March 06, 2019
News Conference News CRT 2017 Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate Michael O'Riordan February 21, 2017